Telehealth & Digital Health

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

The first-ever Wegovy pill is here. Digital health firm eMed is partnering with Novo Nordisk to offer it, promising a new era of guided, responsible care.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

Registration is open for the 2026 Connect Summit, a key event uniting tech, policy, and healthcare leaders to tackle social care challenges.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Internationally recognized fetal surgeon Dr. Jena Miller joins CHOP, signaling a new chapter in minimally invasive procedures for the world's most fragile patients.

A new initiative is tackling the fear and distrust that costs patients their health and the system trillions. Is 'cognitive safety' healthcare's next frontier?

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

New AMA codes for PolarityBio's SkinTE signal a strategic step toward commercialization, aiming to ease clinical adoption for chronic wound care.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

RxSight will showcase its unique post-surgery adjustable lens at J.P. Morgan, facing investor questions on growth in a competitive ophthalmology market.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

With recent FDA approval, Belgian MedTech firm Nyxoah prepares for a pivotal presentation of its unique, battery-free sleep apnea implant at JPM.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.